

## Highlights of This Issue 3999

### SPECIAL FEATURES

#### CCR Translations

- 4001 | **How to Develop Treatments for Biologically Heterogeneous "Diseases"**  
Richard M. Simon  
*See article p. 4004*

#### Statistics in Clinical Cancer Research

- 4004 | **Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819**  
Mary W. Redman, John J. Crowley, Roy S. Herbst, Fred R. Hirsch, and David R. Gandara  
*See commentary p. 4001*

#### Molecular Pathways

- 4013 | **Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia**  
Sarah E.M. Herman and Amy J. Johnson
- 4019 | **Molecular Pathways: Involving Microenvironment Damage Responses in Cancer Therapy Resistance**  
Yu Sun and Peter S. Nelson

#### HUMAN CANCER BIOLOGY

- 4026 | **Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma**  
Katja Harbst, Johan Staaf, Martin Lauss, Anna Karlsson, Anna Måsbäck, Iva Johansson, Pär-Ola Bendahl, Johan Vallon-Christersson, Therese Törngren, Henrik Ekedahl, Jürgen Geisler, Markus Höglund, Mattias Ringnér, Lotta Lundgren, Karin Jirström, Håkan Olsson, Christian Ingvar, Åke Borg, Hensin Tsao, and Göran Jönsson

- 4037 | **Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2**  
Ling-Yen Chung, Shye-Jye Tang, Guang-Huan Sun, Teh-Ying Chou, Tien-Shun Yeh, Sung-Liang Yu, and Kuang-Hui Sun

- 4048 | **EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival**  
Michiel Smits, Sjoerd van Rijn, Esther Hulleman, Dennis Biesmans, Dannis G. van Vuurden, Marcel Kool, Christine Haberler, Eleonora Aronica, W. Peter Vandertop, David P. Noske, and Thomas Würdinger

- 4059 | **Overexpression of GOLPH3 Promotes Proliferation and Tumorigenicity in Breast Cancer via Suppression of the FOXO1 Transcription Factor**  
Zhaolei Zeng, Huanxin Lin, Xiaohui Zhao, Guanglin Liu, Xi Wang, Ruihua Xu, Kun Chen, Jun Li, and Libing Song

#### CANCER THERAPY: PRECLINICAL

- 4070 | **Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts**  
Gaspar J. Kitange, Ann C. Mladek, Brett L. Carlson, Mark A. Schroeder, Jenny L. Pokorny, Ling Cen, Paul A. Decker, Wenting Wu, Gwen A. Lomberk, Shiv K. Gupta, Raul A. Urrutia, and Jann N. Sarkaria

- 4080 | **IGKV3 Proteins as Candidate "Off-the-Shelf" Vaccines for Kappa-Light Chain-Restricted B-Cell Non-Hodgkin Lymphomas**  
Debora Martorelli, Massimo Guidoboni, Valli De Re, Elena Muraro, Riccardo Turrini, Anna Merlo, Elisa Pasini, Laura Caggiari, Luca Romagnoli, Michele Spina, Roberta Mortarini, Daniela Gasparotto, Mario Mazzucato, Antonino Carbone, Antonio Rosato, Andrea Anichini, and Riccardo Dolcetti

4092 **The Antibody-Based Delivery of Interleukin-12 to the Tumor Neovasculature Eradicates Murine Models of Cancer in Combination with Paclitaxel**

Nadine Pasche, Sarah Wulfhart, Francesca Pretto, Elisa Carugati, and Dario Neri

4104 **Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling**

Changgeng Qian, Cheng-Jung Lai, Rudi Bao, Da-Gong Wang, Jing Wang, Guang-Xin Xu, Ruzanna Atoyian, Hui Qu, Ling Yin, Maria Samson, Brian Zifcak, Anna Wai See Ma, Steven DellaRocca, Mylissa Borek, Hai-Xiao Zhai, Xiong Cai, and Maurizio Voi

4114 **Metronomic Activity of CD44-Targeted Hyaluronic Acid-Paclitaxel in Ovarian Carcinoma**

Sun Joo Lee, Sukhen C. Ghosh, Hee Dong Han, Rebecca L. Stone, Justin Bottsford-Miller, De Yue Shen, Edmond J. Auzenne, Alejandro Lopez-Araujo, Chunhua Lu, Masato Nishimura, Chad V. Pecot, Behrouz Zand, Duangmani Thanappapasr, Nicholas B Jennings, Yu Kang, Jie Huang, Wei Hu, Jim Klostergaard, and Anil K. Sood

## IMAGING, DIAGNOSIS, PROGNOSIS

4122 **Progenitor-like Traits Contribute to Patient Survival and Prognosis in Oligodendroglial Tumors**

Felicia Soo-Lee Ng, Tan Boon Toh, Esther Hui-Ling Ting, Geraldene Rong-Hui Koh, Edwin Sandanaraj, Mark Phong, Swee Seong Wong, Siew Hong Leong, Oi Lian Kon, Greg Tucker-Kellogg, Wai Hoe Ng, Ivan Ng, Carol Tang, and Beng Ti Ang

4136 **Breast Cancer Cell Targeting by Prenylation Inhibitors Elucidated in Living Animals with a Bioluminescence Reporter**

Sharon L. Chinault, Julie L. Prior, Kevin M. Kaltenbronn, Anya Penly, Katherine N. Weilbaecher, David Piwnicka-Worms, and Kendall J. Blumer

4145 **The Prognostic Significance of Vasohibin-1 Expression in Patients with Upper Urinary Tract Urothelial Carcinoma**

Yasumasa Miyazaki, Takeo Kosaka, Shuji Mikami, Eiji Kikuchi, Nobuyuki Tanaka, Takahiro Maeda, Masaru Ishida, Akira Miyajima, Ken Nakagawa, Yasunori Okada, Yasufumi Sato, and Mototsugu Oya

4154 **Performance of p16/Ki-67 Immunostaining to Detect Cervical Cancer Precursors in a Colposcopy Referral Population**

Nicolas Wentzensen, Lauren Schwartz, Rosemary E. Zuna, Katie Smith, Cara Mathews, Michael A. Gold, R. Andy Allen, Roy Zhang, S. Terence Dunn, Joan L. Walker, and Mark Schiffman

4163 **ERG Rearrangement for Predicting Subsequent Cancer Diagnosis in High-Grade Prostatic Intraepithelial Neoplasia and Lymph Node Metastasis**

Xin Gao, Liao-Yuan Li, Fang-Jian Zhou, Ke-Ji Xie, Chun-Kui Shao, Zu-Lan Su, Qi-Peng Sun, Ming-Kun Chen, Jun Pang, Xiang-Fu Zhou, Jian-Guang Qiu, Xing-Qiao Wen, Ming Yang, Xian-Zhong Bai, Hao Zhang, Li Ling, and Zhong Chen

## CANCER THERAPY: CLINICAL

4173 **A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors**

David S. Hong, Daniel W. Bowles, Gerald S. Falchook, Wells A. Messersmith, Goldy C. George, Cindy L. O'Bryant, Alex C. H. Vo, Kevin Klucher, Roy S. Herbst, S. Gail Eckhardt, Scott Peterson, Diana F. Hausman, Razelle Kurzrock, and Antonio Jimeno

## PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

4183 **Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type**

Yoshinori Ito, Hiroshi Kimura, Yoshinobu Maeda, Chizuko Hashimoto, Fumihiko Ishida, Koji Izutsu, Noriyasu Fukushima, Yasushi Isobe, Jun Takizawa, Yuichi Hasegawa, Hajime Kobayashi, Seiichi Okamura, Hikaru Kobayashi, Motoko Yamaguchi, Junji Suzumiya, Rie Hyo, Shigeo Nakamura, Keisei Kawa, Kazuo Oshimi, and Ritsuro Suzuki

4191 **Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration**

Ke Lin, Janet Adamson, Gillian G. Johnson, Anthony Carter, Melanie Oates, Rachel Wade, Sue Richards, David Gonzalez, Estella Matutes, Claire Dearden, David G. Oscier, Daniel Catovsky, and Andrew R. Pettitt

4201 **TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep)**

Lai Ling Cheng, Yoko Itahana, Zheng Deng Lei, Na-Yu Chia, Yonghui Wu, Yingnan Yu, Shen Li Zhang, Aye Aye Thike, Anuradha Pandey, Steve Rozen, Pieter Mathijs Voorhoeve, Qiang Yu, Puay Hoon Tan, Boon Huat Bay, Koji Itahana, and Patrick Tan

## LETTERS TO THE EDITOR

4213 **Lifetime Cancer Risks of PTEN Mutation Carriers—Letter**

Molly S. Daniels, Thereasa Rich, Scott Weissman, and Robert Pilarski

4214 **Lifetime Cancer Risks of PTEN Mutation Carriers—Response**

Min-Han Tan, Jessica Mester, and Charis Eng


## CORRECTIONS

4215 **Correction: New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy**

4216 **Correction: *MicroRNA-148a* Suppresses Tumor Cell Invasion and Metastasis by Downregulating *ROCK1* in Gastric Cancer**

## ABOUT THE COVER

The recently discovered recurrent ERG rearrangement is highly specific for prostate cancer. There are significant associations of ERG rearrangement in preoperative biopsies with pelvic lymph node metastasis for patients with prostate cancer. The fluorescence *in situ* hybridization image shows representative nuclei of a prostate cancer gland. One yellow/one green/one red in a nucleus represents abnormal signal patterns indicative of an ERG rearrangement. For details, please see the article by Gao and colleagues on page 4163 of this issue.



# Clinical Cancer Research

**18 (15)**

*Clin Cancer Res* 2012;18:3999-4216.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/18/15>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/18/15>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.